A total of 206 patients were enrolled in the open-label period, and 205 were treated with omalizumab. At baseline, patients enrolled in the XTEND-CIU study reported a substantial disease burden, reflected in the UAS7 (mean, 32.2; standard deviation, 7.0) and patient-reported outcome (PRO) scores, despite treatment with H 1 antihistamines, H 2 blockers, and/or leukotriene receptor modifiers.
By week 1, 3.9% of patients had achieved a UAS7 of 6 or lower; complete response was evident as early as week 2 in 13.7% of patients, and improvements continued to week 24. The percentages of patients meeting the definition of protocol-defined responder or complete responder, respectively, were as follows: 38.2% and 17.6% at week 4, 58.8% and 36.8% at week 12, and 73.0% and 52.0% at week 24 (Fig 2) . Among protocol-defined nonresponders (ie, nonrandomized patients), 64% experienced an improvement in their UAS7 of 10 or more between baseline and the end of week 24.
PRO measures showed improvement in all evaluated areas; the most notable improvement occurred between baseline and week 12, with additional improvement achieved by week 24. Even protocol-defined nonresponders reported evidence of clinically meaningful improvement (achievement of a minimally important difference Patients in the XTEND-CIU study had a disease burden consistent with that described in other large studies. [3] [4] [5] [6] The rate of protocol-defined response at randomization was 65% at week 24, exceeding the expected 57% response rate at week 24 according to data from the GLACIAL study, which enrolled a population similar to that of the current study. 3 These preliminary findings from the XTEND-CIU study, reflecting the initial 24-week open-label period, demonstrate that in patients with evidence of moderate-to-severe CIU symptoms at baseline, improvements in the UAS7 were observed as early as week 1 and continued to week 24, with PROs following a similar trend. Even among protocol-defined nonresponders there was evidence of a treatment response. Data from the double-blind period of the XTEND-CIU study will enhance understanding of the safety and efficacy of longer-term (48 weeks) administration of omalizumab in patients with CIU. 
